State-of-the-art MS technology applications in lung disease

Bioanalysis

Volumn 3, Issue 23, 2011, Pages 2665-2677

  Végvri, Akos ^a   Dme, Balzs ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c National Kornyi Institute of Pulmonology   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ERLOTINIB; GEFITINIB; PROGASTRIN RELEASING PEPTIDE; TIOTROPIUM BROMIDE;

ANALYTIC METHOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HUMAN; INTERMETHOD COMPARISON; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR IMAGING; PATHOGENESIS; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; REVIEW; TISSUE MICROARRAY;

HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MASS SPECTROMETRY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 82955168436     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.271     Document Type: Review

References (127)

1. Végvári Á, Marko-Varga G. Clinical protein science and bioanalytical mass spectrometry with an emphasis on lung cancer. Chem. Rev. 110(5), 3278-3298 (2010).
2. Marko-Varga G, Fehniger TE. Proteomics and disease: the challenges for technology and discovery. J. Proteome Res. 3(2), 167-178 (2004). (Pubitemid 38500983)
3. Hortin GL, Carr SA, Anderson NL. Advances in protein analysis for the clinical laboratory. Clin. Chem. 56(2), (2010).
4. Cox J, Mann M. Is proteomics the new genomics? Cell 130(3), 395-398 (2007). (Pubitemid 47198310)
5. Lu BW, Motoyama A, Ruse C, Venable J, Yates JR. Improving protein identifcation sensitivity by combining MS and MS/MS information for shotgun proteomics using LTQ-Orbitrap high mass accuracy data. Anal. Chem. 80(6), 2018-2025 (2008). (Pubitemid 351458047)
6. Nesvizhskii AI, Vitek O, Aebersold R. Analysis and validation of proteomic data generated by tandem mass spectrometry Nat. Methods 4(10), 787-797 (2007). (Pubitemid 350055575)
7. Malmström J, Lee H, Aebersold R. Advances in proteomic workfows for systems biology Curr. Opin Biotechnol. 18(4), 378-384 (2007). (Pubitemid 47385185)
8. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56(2), 177-185 (2010).
9. Davis MT, Auger PL, Patterson SD. Cancer biomarker discovery via low-molecular-weight serum profling: are we following circular paths? Clin. Chem. 56(2), 244-247 (2010).
10. Meistermann H, Norris JL, Aerni HR et al. Biomarker discovery by imaging mass spectrometry. transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol. Cell. Proteomics 5(10), 1876-1886 (2006). (Pubitemid 44688196)
11. Voshol H, Ehrat M, Traenkle J, Bertrand E, Van Oostrum J. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J. 276(23), 6871-6879 (2009).
12. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Cancer J. Clin. 61(2), 69-90 (2011).
13. Török S, Hegedüs B, László V et al. Lung cancer in never smokers. Future Oncol. 7(10), 1195-1211 (2011).
14. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J. Thorac. Oncol. 6(9), 1601-1612 (2011).
15. Mok TS, Wu YL, Thongprasert S et al. Geftinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
16. Okano T, Kondo T, Fujii K et al. Proteomic signature corresponding to the response to geftinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin. Cancer Res. 13(3), 799-805 (2007). (Pubitemid 46340352)
17. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 304(5676), 1497-1500 (2004). (Pubitemid 38720929)
18. Kudoh S, Kato H, Nishiwaki Y et al. Interstitial lung disease in Japanese patients with lung cancer-a cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 177(12), 1348-1357 (2008). (Pubitemid 351860912)
19. Chen HY, Yu SL, Chen CH et al. A fve-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356(1), 11-20 (2007).
20. Breathnach OS, Freidlin B, Conley B et al. Twenty-two years of Phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 19(6), 1734-1742 (2001). (Pubitemid 32230875)
21. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin. Oncol. 30(3), 34-46 (2003). (Pubitemid 36828626)
22. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N. Engl. J. Med. 350(21), 2129-2139 (2004). (Pubitemid 38637993)
23. Nishimura T, Kato H, Ikeda N, Kihara M, Nomura F, Marko-Varga G. Drug characteristics on targeted cancer phenotypes within Japanese health care. Expert Rev. Clin. Pharmacol. 4, accepted for publication (2011).
24. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11), e442 (2006).
25. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 374(9691), 733-743 (2009).
26. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378(9795), 1015-1026 (2011).
27. Young RP, Hopkins RJ. How the genetics of lung cancer may overlap with COPD. Respirology 16(7), 1047-1055 (2011).
28. Yang IA, Relan V, Wright CM et al. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther. Targets 15(4), 439-456 (2011).
29. Rooney C, Sethi T. The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer. Respiration 81(2), 89-104 (2011).
30. Han MK. Update in chronic obstructive pulmonary disease in 2010. Am. J. Respir. Crit. Care Med. 183(10), 1311-1315 (2011).
31. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005). (Pubitemid 41746029)
32. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat. Biotechnol. 24(8), 971-983 (2006). (Pubitemid 44215392)
33. Schiess R, Wollscheid B, Aebersold R. Targeted proteomic strategy for clinical biomarker discovery Mol. Oncol. 3(1), 33-44 (2009).
34. Brown H. Turning the Stockholm Declaration into reality: creating a world-class infrastructure for cancer research in Europe. Mol. Oncol. 3(1), 5-8 (2009).
35. Gutman S, Kessler LG. The US FDA perspective on cancer biomarker development. Nat. Rev. Cancer 6(7), 565-571 (2006).
36. Nomura M, Fukuda T, Fujii K et al. Preferential expression of potential markers for cancer stem cells in large cell neuroendocrine carcinoma of the lung. an FFPE preomice study. J. Clin. Bioinformatics 1, 23 (2011).
37. Nyberg F, Ogiwara A, Harbron CG et al. Proteomic biomarkers for acute interstitial lung disease in geftinib-treated Japanese lung cancer patients. Plos One 6(7), e22062 (2011).
38. Lu B, Xu T, Park SK, Yates JR. Shotgun protein identifcation and quantifcation by mass spectrometry. Methods Mol. Biol. 564, 261-288 (2009).
39. Mann M. Comparative analysis to guide quality improvements in proteomics. Nat. Methods 6(10), 717-719 (2009).
40. Olsen JV, Schwartz JC, Griep-Raming J et al. A dual pressure linear ion trap orbitrap instrument with very high sequencing speed. Mol. Cell. Proteomics 8(12), 2759-2769 (2009).
41. Schmidt A, Claassen M, Aebersold R. Directed mass spectrometry: towards hypothesis-driven proteomics. Curr. Opin Chem. Biol. 13(5-6), 510-507 (2009).
42. Gilchrist A, Au CE, Hiding J et al. Quantitative proteomics analysis of the secretory pathway. Cell 127(6), 1265-1281 (2006). (Pubitemid 44914006)
43. Anderson NL, Anderson NG. The human plasma proteome: history, character and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002).
44. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 312(5771), 212-217 (2006).
45. Marko-Varga G, Ogiwara A, Nishimura T et al. Personalized medicine and proteomics: lessons from non-small cell lung cancer. J. Proteome Res. 6(8), 2925-2935 (2007). (Pubitemid 47315558)
46. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass-spectrometry of large biomolecules. Science 246(4926), 64-71 (1989). (Pubitemid 19252085)
47. Karas M, Bahr U, Hillenkamp F. UV laser matrix desorption ionization mass-spectrometry of proteins in the 100,000 dalton range. Int. J. Mass Spectrom. Ion Processes 92, 231-242 (1989).
48. Tanaka K, Waki H, Ido Y et al. Protein and polymer analyses up to m/z 100,000 by laser ionization time-of-fight mass spectrometry Rapid Commun. Mass Spectrom. 2(8), 151-153 (1988).
49. Kato H, Nishimura T, Hirano T et al. A clinician view and experience of proteomic studies in the light of lung cancer in Japanese healthcare. J. Proteome Res. 10(1), 51-57 (2010).
50. Hober S, Uhlen M. Human protein atlas and the use of microarray technologies. Curr. Opin Biotechnol. 19(1), 30-35 (2008).
51. Kim K, Kim SJ, Yu HG et al. Verifcation of biomarkers for diabetic retinopathy by multiple reaction monitoring. J. Proteome Res. 9(2), 689-699 (2010).
52. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantifcation through mass spectrometry-based approaches: current strategies for candidate verifcation. Clin. Chem. 56(2), 212-222 (2010).
53. Gstaiger M, Aebersold R. Applying mass spectrometry-based proteomics to genetics, genomics and network biology Nat. Rev. Genet. 10(9), 617-627 (2009).
54. Abbatiello SE, Mani DR, Keshishian H, Carr SA. Automated detection of inaccurate and imprecise transitions in peptide quantifcation by multiple reaction monitoring mass spectrometry. Clin. Chem. 56(2), 291-305 (2010).
55. Stahl-Zeng J, Lange V, Ossola R et al. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol. Cell. Proteomics 6(10), 1809-1817 (2007). (Pubitemid 350031682)
56. Martin DB, Holzman T, May D et al. MRMer, an interactive open source and cross-platform system for data extraction and visualization of multiple reaction monitoring experiments. Mol. Cell. Proteomics 7(11), 2270-2278 (2008).
57. Blair IA, Tilve A. Analysis of anticancer drugs and their metabolites by mass spectrometry Curr. Drug Metab. 3(5), 463-480 (2002). (Pubitemid 34982180)
58. Kuhn J, Gotting C, Kleesiek K. Simultaneous measurement of amiodarone and desethylamiodarone in human plasma and serum by stable-isotope dilution liquid chromatography-tandem mass spectrometry assay. J. Pharm. Biomed. Anal. 51(1), 210-216 (2010).
59. Hopfgartner G, Bourgogne E. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry Mass Spec trom. Rev. 22(3), 195-214 (2003).
60. Bunk DM, Welch MJ. Electrospray ionization mass spectrometry for the quantitation of albumin in human serum. J. Am. Soc. Mass Spectrom. 8(12), 1247-1254 (1997). (Pubitemid 28487050)
61. Steen H, Pandey A. Proteomics goes quantitative: measuring protein abundance. Trends Biotechnol. 20(9), 361-364 (2002). (Pubitemid 34880164)
62. Barnidge DR, Dratz EA, Martin T, Bonilla LE, Moran LB, Lindall A. Absolute quantifcation of the G protein-coupled receptor rhodopsin by LC-MS/MS using proteolysis product peptides and synthetic peptide standards. Anal. Chem. 75(3), 445-451 (2003). (Pubitemid 36176714)
63. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantifcation of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and C-13-labeled peptide standards. Proteomics 4(4), 1175-1186 (2004). (Pubitemid 38445974)
64. Barr JR, Maggio VL, Patterson DG et al Isotope dilution mass spectrometric quantifcation of specifc proteins: model application with apolipoprotein A-I. Clin. Chem. 42(10), 1676-1682 (1996). (Pubitemid 26354748)
65. Kippen AD, Cerini F, Vadas L et al. Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and type II diabetic individuals with comparison to immunoassay J. Biol. Chem. 272(19), 12513-12522 (1997). (Pubitemid 27203343)
66. Stocklin R, Vu L, Vadas L et al. Stable-isotope dilution assay for the in vivo determination of insulin levels in humans by mass spectrometry. Diabetes 46(1), 44-50 (1997). (Pubitemid 27009948)
67. Fortin T, Salvador A, Charrier JP et al. Multiple reaction monitoring cubed for protein quantifcation at the low nanogram/milliliter level in nondepleted human serum. Anal. Chem. 81(22), 9343-9352 (2009).
68. Anderson NL, Anderson NG, Pearson TW et al. A human proteome detection and quantitation project. Mol. Cell. Proteomics 8(5), 883-886 (2009).
69. Rezeli M, Végvári Á, Ottervald J, Olsson T, Laurell T, Marko-Varga G. MRM assay for quantitation of complement components in human blood plasma: a feasibility study on multiple sclerosis. J. Proteomics doi:10.1016/j. jprot.2011.05.042 (2011) (Epub ahead of print).
70. Gerber SA, Rush J, Stemman O, Kirschner MW, Gygi SP. Absolute quantifcation of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl Acad. Sci. USA 100(12), 6940-6945 (2003). (Pubitemid 36706372)
71. Mallick P, Schirle M, Chen SS et al. Computational prediction of proteotypic peptides for quantitative proteomics. Nat. Biotechnol. 25(1), 125-131 (2007). (Pubitemid 46098780)
72. Gralla RJ, Gatzemeier U, Gebbia V, Huber R, O'Brien M, Puozzo C. Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management. Drugs 67(10), 1403-1410 (2007). (Pubitemid 47026390)
73. Honeywell R, Laan AC, Van Groeningen CJ et al. The determination of gemcitabine and 2́-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry J. Chromatogr. B 847(2), 142-152 (2007). (Pubitemid 46331023)
74. Honeywell R, Yarzadah K, Giovannetti E et al. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J. Chromatogr. B 878(15-16), 1059-1068 (2010).
75. Qian J, Wang YX, Chang JH, Zhang JA, Wang JL, Hu XC. Rapid and sensitive determination of vinorelbine in human plasma by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application. J. Chromatogr. B 879(9-10), 662-668 (2011).
76. Zheng X, Hu P, Liu J et al. LC-MS/MS quantitative determination of geftinib in human serum and cerebrospinal fuid. Chromatographia 74(1-2), 41-49 (2011).
77. Bhat SH, Gelhaus SL, Mesaros C, Vachani A, Blair IA. A new liquid chromatography/mass spectrometry method for 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanol (NNAL) in urine. Rapid Commun. Mass Spectrom. 25(1), 115-121 (2011).
78. Rangiah K, Hwang WT, Mesaros C, Vachani A, Blair IA. Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine & its 15 metabolites by LC-MS. Bioanalysis 3(7), 745-761 (2011).
79. Chappell GP, Xiao XY, Pica-Mendez A et al. Quantitative measurement of cysteinyl leukotrienes and leukotriene B(4) in human sputum using ultra high pressure liquid chromatography-tandem mass spectrometry J. Chromatogr. B 879(3-4), 277-284 (2011).
80. Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem. Res. Toxicol. 21(1), 160-171 (2008). (Pubitemid 351219717)
81. Crawford J, Orourke M, Schiller JH et al. Randomized trial of vinorelbine compared with fuorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 14(10), 2774-2784 (1996). (Pubitemid 26329664)
82. Montuschi P, Sala A, Dahlen SE, Folco G. Pharmacological modulation of the leukotriene pathway in allergic airway disease. Drug Discov. Today 12(9-10), 404-412 (2007). (Pubitemid 46636374)
83. Fehniger TE, Marko-Varga GA. Clinical Proteomics Today J. Proteome Res. 10(1), 3-3 (2011).
84. Fehniger TE, Marko-Varga G. Proteomics and disease revisited: the challenge of providing proteomic tools into clinical practice. J. Proteome Res. 9(3), 1191-1192 (2010).
85. Kato H, Nishimura T, Ikeda N et al. Developments for a growing Japanese patient population: facilitating new technologies for future health care. J. Proteomics 74(6), 759-764 (2011).
86. Ueda KUK, Saichi N, Takami S et al. A comprehensive peptidome profling technology for the identifcation of early detection biomarkers for lung adenocarcinoma. Plos One 6(4), (2011).
87. Sung HJ, Cho JY Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep. 41(9), 615-625 (2008).
88. Goldstraw P, Crowley J, Chansky K et al. The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classifcation of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007). (Pubitemid 47357522)
89. Ostroff RM, Bigbee WL, Franklin W et al. Unlocking biomarker discovery: large-scale application of aptamer proteomic technology for early detection of lung cancer. Plos One 5(12), e15003 (2010).
90. Winther B, Moi P, Nordlund MS, Lunder N, Paus E, Reubsaet JLE. Absolute ProGRP quantifcation in a clinical relevant concentration range using LC-MS/MS and a comprehensive internal standard. J. Chromatogr. B 877(13), 1359-1365 (2009).
91. Nordlund MS, Warren DJ, Nus-Tad K, Bjerner J, Paus E. Automated time-resolved immunofuorometric assay for progastrin-releasing peptide. Clin. Chem. 54(5), 919-922 (2008). (Pubitemid 351671611)
92. Zhang HX, Liu QF, Zimmerman LJ et al. Methods for peptide and protein quantitation by liquid chromatography-multiple reaction monitoring mass spectrometry. Mol. Cell. Proteomics 10(6), M110.006593 (2011).
93. Nishimura T, Nomura M, Tojo H et al. Proteomic analysis of laser-microdissected paraffn-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. J. Proteomics 73 (6), 1100-1110 (2010).
94. Wei YH, Tong JF, Taylor P et al. Primary tumor xenografts of human lung Adeno and squamous cell carcinoma express distinct proteomic signatures. J. Proteome Res. 10(1), 161-174 (2011).
95. Kawamura T, Nomura M, Tojo H et al. Proteomic analysis of laser-microdissected paraffn-embedded tissues: (1) stage-related protein candidates upon non-metastatic lung adenocarcinoma. J. Proteomics 73(6), 1089-1099 (2010).
96. Bonnel D, Legouffe R, Willand N et al. MALDI imaging techniques dedicated to drug-distribution studies. Bioanalysis 3(12), 1399-1406 (2011).
97. Shanta SR, Kim Y, Kim YH, Kim KP. Application of MALDI tissue imaging of drugs and metabolites: a new frontier for molecular histology. Biomol. Therap. 19(2), 149-154 (2011).
98. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal. Chem. 69(23), 4751-4760 (1997).
99. Bhattacharya SH, Gal AA, Murray KK. Laser capture microdissection MALDI for direct analysis of archival tissue. J. Proteome Res. 2(1), 95-98 (2003). (Pubitemid 36207195)
100. Todd PJ, Schaaff TG, Chaurand P, Caprioli RM. Organic ion imaging of biological tissue with secondary ion mass spectrometry and matrix-assisted laser desorption/ionization. J. Mass Spectrom. 36(4), 355-369 (2001). (Pubitemid 32409879)
101. Yanagisawa K, Shyr Y, Xu BGJ et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 3 62(93 82), 433-439 (2003). (Pubitemid 36999706)
102. Marko-Varga G, Fehniger TE, Rezeli M, Döme B, Laurell T, Végvári Á. Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging. J. Proteomics 74(7), 982-992 (2011).
103. Xu BJ, Gonzalez AL, Kikuchi T et al. MALDI-MS derived prognostic protein markers for resected non-small cell lung cancer. Proteom. Clin. Appl. 2(10-11), 1508-1517 (2008).
104. Yanagisawa K, Tomida S, Shimada Y, Yatabe Y, Mitsudomi T, Takahashi T A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J. Natl Cancer Inst. 99(11), 858-867 (2007).
105. Groseclose MR, Massion PR, Chaurand P, Caprioli RM. High-throughput proteomic analysis of formalin-fxed paraffn-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics 8(18), 3715-3724 (2008).
106. Bakry R, Rainer M, Huck CW, Bonn GK. Protein profling for cancer biomarker discovery using matrix-assisted laser desorption/ionization time-of-fight mass spectrometry and infrared imaging: a review. Anal. Chim. Acta 690(1), 26-34 (2011).
107. Cazares LH, Troyer DA, Wang BH, Drake RR, Semmes OJ. MALDI tissue imaging: from biomarker discovery to clinical applications. Anal. Bioanal. Chem. 401(1), 17-27 (2011).
108. Seeley EH, Caprioli RM. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol. 29(3), 136-143 (2011).
109. Nilsson A, Fehniger TE, Gustavsson L et al. Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. Plos One 5(7), e1 1411 (2010).
110. Benabdellah F, Touboul D, Brunelle A, Laprevote O. In situ primary metabolites localization on a rat brain section by chemical mass spectrometry imaging. Anal. Chem. 81(13), 5557-5560 (2009).
111. Bouslimani A, Bec N, Glueckmann M, Hirtz C, Larroque C. Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heat intraoperative chemotherapy (HIPEC)-like treated rat kidney Rapid Commun. Mass Sp. 24(4), 415-421 (2010).
112. Goodwin RJ, Macintyre L, Watson DG, Scullion SP, Pitt AR. A solvent-free matrix application method for matrix-assisted laser desorption/ionization imaging of small molecules. Rapid Commun. Mass Sp. 24(11), 1682-1686 (2010).
113. Reyzer ML, Chaurand P, Angel PM, Caprioli RM. Direct molecular analysis of whole-body animal tissue sections by MALDI imaging mass spectometry. Methods Mo l. Biol. 656, 285-301 (2010).
114. Troendle FJ, Reddick CD, Yost RA. Detection of pharmaceutical compounds in tissue by matrix-assisted laser desorption/ionization and laser desorption/chemical ionization tandem mass spectrometry with a quadrupole ion trap. J. Am. Soc. Mass Spectrom. 10(12), 1315-1321 (1999). (Pubitemid 34506457)
115. Reyzer ML, Hsieh YS, Ng K, Korfmacher WA, Caprioli RM. Direct analysis of drug candidates in tissue by matrix-assisted laser desorption/ionization mass spectrometry J. Mass Spectrom. 38(10), 1081-1092 (2003). (Pubitemid 37407703)
116. Signor L, Varesio E, Staack RF, Starke V, Richter WF, Hopfgartner G. Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-fight mass spectrometry J. Mass Spectrom. 42(7), 900-909 (2007). (Pubitemid 47057072)
117. Schwenk JM, Gry M, Rimini R, Uhlen M, Nilsson P. Antibody suspension bead arrays within serum proteomics. J. Proteome Res. 7(8), 3168-3179 (2008).
118. Weissenstein U, Schneider MJ, Pawlak M et al. Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics 6(5), 1427-1436 (2006).
119. Rinn JL, Rozowsky JS, Laurenzi IJ et al. Major molecular differences between mammalian sexes are involved in drug metabolism and renal function. Dev. Cell 6(6), 791-800 (2004). (Pubitemid 38745414)
120. Cho CR, Labow M, Reinhardt M, Van Oostrum J, Peitsch MC. The application of systems biology to drug discovery Curr. Opin Chem. Biol. 10(4), 294-302 (2006). (Pubitemid 44080655)
121. Apweiler R, Aslanidis C, Deufel T et al. Approaching clinical proteomics: current state and future felds of application in cellular proteomics. Cytometry A 75(10), 816-832 (2009).
122. Paavilainen L, Edvinsson A, Asplund A et al. The impact of tissue fxatives on morphology and antibody-based protein profling in tissues and cells. J. Histochem. Cytochem. 58(3), 237-246 (2010).
123. Pawlak M, Schick E, Bopp MA, Schneider MJ, Oroszlan P, Ehrat M. Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2(4), 383-393 (2002). (Pubitemid 34429356)
124. Pontén F, Gry M, Fagerberg L et al. A global view of protein expression in human cells, tissues, and organs. Mol. Syst. Biol. 5, 337 (2009).
125. Bodenmiller B, Mueller LN, Pedrioli PGA et al. An integrated chemical, mass spectrometric and computational strategy for (quantitative) phosphoproteomics: application to drosophila melanogaster Kc167 cells. Mol. BioSyst. 3(4), 275-286 (2007). (Pubitemid 46456312)
126. Price ND, Foltz G, Madan A, Hood L, Tian Q. Systems biology and cancer stem cells. J. Cell. Mol. Med. 12(1), 97-110 (2008).
127. Auffray C, Chen Z, Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med. 1(1), 2 (2009).